
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics Inc is currently positioned favorably within the pharmaceutical sector, particularly due to its focus on stenoparib, an oral inhibitor demonstrating promising and durable clinical benefits for patients with advanced recurrent ovarian cancer. The company’s proprietary Drug Response Predictor technology enhances patient selection, which is anticipated to improve clinical outcomes and support the overall efficacy of its treatment approach. Positive clinical data indicating a median overall survival exceeding 25 months in Phase 2 trials, combined with attractive valuation metrics, underscores the potential for significant upside, reflecting a robust outlook for the company's stock.
Bears say
Allarity Therapeutics Inc reported a net loss of $2.8 million with an earnings per share (EPS) of $(0.19), which was slightly better than previous estimates but still indicates ongoing financial challenges. The company faces significant risks, including liquidity concerns, potential failure of its drug candidates in clinical trials, and regulatory hurdles that could hinder commercialization efforts. Furthermore, external factors such as competition, reimbursement issues, and shifting investor sentiment toward biotech stocks contribute to a challenging outlook for the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares